Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCARH109 CAR T Cells in Multiple Myeloma
NCT04555551Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GPRC5D-CAR-T in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Sep 2020; status: active, not recruiting.
02
Drugs
GPRC5D-CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04555551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555551.